Antiviral drugs in current clinical use

Journal of Clinical Virology

Volumn 30, Issue 2, 2004, Pages 115-133

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral drugs; CMV; HBV; HCV; HIV; HSV; Influenza; RSV; VZV

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACICLOVIR; ADEFOVIR DIPIVOXIL; AMANTADINE; AMPRENAVIR; ANTIVIRUS AGENT; CIDOFOVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET SODIUM; GANCICLOVIR; IDOXURIDINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NETIVUDINE; NEVIRAPINE; OSELTAMIVIR; PENCICLOVIR; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIALIDASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUDOX; ZALCITABINE; ZANAMIVIR; ZERPEX; ZIDOVUDINE; ZOSTEX;

CHRONIC HEPATITIS; HEPATITIS B VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS B; HERPES SIMPLEX; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS DISEASES;

EID: 2342531101     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.02.009     Document Type: Review

References (17)

1. De Clercq E. Antiviral drugs: current state of the art. J. Clin. Virol. 22:2001;73-89
2. De Clercq E. Strategies in the design of antiviral drugs. Nat. Rev. Drug. Discovery. 1:2002;13-25
3. De Clercq E. Antiviral activity of nucleoside analogues: the BVDU connection. In: Chu CK, editor. Recent advances in nucleosides: chemistry and chemotherapy. Amsterdam: Elsevier; 2002b. p. 433-54.
4. De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev. Anti-Infect Ther. 1:2003;21-43
5. De Clercq E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J. Antimicrob. Chemother. 51:2003;1079-1083
6. De Clercq E. The bicyclam AMD3100 story. Nat. Rev. Drug. Discovery. 2:2003;581-587
7. De Clercq E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic fluro [2, 3-d]pyrimidine nucleoside analogues. Med. Res. Rev. 23:2003;253-274
8. De Clercq E. HIV chemotherapy and-prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol, in press.
9. Doms R.W., Moore J.P. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:2000;F9-13
10. Eizuru Y. Development of new antivirals for herpesviruses. Antiviral Chem. Chemother. 14:2003;299-308
11. Hadziyannis S.J., Tasspoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:2003;800-807
12. Hussar D.A. The HIV protease inhibitors. The Drug Advisor. 2:2003;1-16
13. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2003;2175-2185
14. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 426:2003;186-189
15. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2003;2186-2195
16. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:2003;808-816
17. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Ther 2004;9:57-65.